Eugit Therapeutics GTM brain

Eugit Therapeutics is developing tissue-targeted therapeutic delivery for inflammatory disease, initially inflammatory bowel disease.

market profile

text: Non-specific delivery can expose healthy tissue to drugs; Eugit is developing a T cell receptor based approach aimed at diseased tissue.
text: The current IBD delivery strategy differs from its original YC launch on engineered cell therapy for solid tumors. Confirm present programs before outreach.

title: Pharmaceutical immunology business development lead
pains:
- Systemic exposure can constrain promising inflammatory disease therapies
- Needs convincing tissue selectivity, compatible payloads and clear rights before funding a platform deal
title: IBD translational medicine leader
pains:
- Current therapies do not work for all patients or may lose effectiveness
- Preclinical localization needs to translate into clinical safety and meaningful outcomes
title: Drug delivery research director
pains:
- Needs to show that tissue targeting works with an actual therapeutic payload
- Must evaluate biodistribution and off-target effects before clinical development

text: Potential pharmaceutical and biotech collaborators with IBD or other tissue-specific inflammatory disease assets; partnership targeting is inferred from the platform and grant, not a disclosed customer list.
text: Potential partners have translational research and clinical development capacity; target revenue, headcount and transaction criteria are undisclosed.

objection: Has the platform improved outcomes or safety in people?
response: Request current biodistribution, toxicology and clinical trial status; delivery and treatment benefit are still hypotheses requiring validation.
objection: Will it work with our payload?
response: Discuss payload compatibility, tissue selectivity and a staged feasibility study with the research team.
objection: Is oncology or IBD the company's current priority?
response: Ask the founders to confirm current programs because the historical launch and current description differ.

name: Oragen Therapeutics
website: https://oragen-therapeutics.com/
why: Develops an oral genetic medicine platform targeting inflamed gut tissue in IBD, with a different delivery modality.
name: Biora Therapeutics
website: https://www.bioratherapeutics.com/pipeline/navicap-targeted-therapeutic-delivery-platform
why: NaviCap uses an ingestible device for IBD tissue delivery; its prior corporate entity sold assets in bankruptcy, so confirm current ownership and activity.

name: Nizar Batada
url: https://www.ycombinator.com/founders/nizar-batada
why: Co-founder and CEO leading the company.
name: George Church
url: https://fundraisingfox.com/people/george-church
why: Scientific advisor and co-founder with a synthetic biology research network.

text: An immunology drug developer seeks tissue-selective delivery to reduce systemic exposure.
text: A pharma team expands IBD development or searches for external therapeutic delivery platforms.

model: unknown

unknown

low

name: Nizar Batada
title: Founder/CEO
role: CEO
bio: Nizar is the co-founder and CEO at EUGIT, which he started with George Church in 2022. He is an expert in cancer research, genomics and bioinformatics and has published over 25 articles in peer-reviewed journals such as Nature and has obtained nationally competitive grants. Prior to EUGIT, he was a scientist at 23andMe and a tenure track lecturer at the University of Edinburgh, UK. Nizar grew up in Toronto and obtained his PhD in Biophysics from Stanford.